





Estd. 1950 ISO 9001: 2015 Certified Institution

Ref: ISB/CR/17/19

Date: 09/4/2019

#### CIRCULAR-17

### **Tdap vaccinations for Class VIII**

Dear Parent

Please be informed that as per the directive received from the Ministry of Health, all the students of Class VIII should receive the Tdap Booster vaccination. The students those who have received the vaccination, or have any medical issue to receive the vaccination should attach the documents along with the Consent Form.

It is compulsory for all the students to return the duly filled consent form (attached) to the Class Teachers on or before 16.04.2019.

With regards,

V R Palaniswamy Principal



~
<del></del>
<u>ACKNOWLEDGEMENT</u>

## Tdap vaccinations for Class VIII

acknowledge	the	receipt	of	Circular	No.	17	dated	09/04/2019	sent	through	my	ward
									GR	No.		

	GRI	No.
of Class / Section .		ANSCA
Name of Parent:	Signature	AND STERRED OF
Date:		14(88A) \

# KINGDOM OF BAHRAIN Ministry of Health



مَمْلَكَةُ البَحْنَيْنُ وَ الْوَلَّا الصِّلْحِثِ مِنْ rain CHOOS OF THE PARTY OF THE


Recommended Immunization Schedule in the Kingdom of Bahrain

	CHIL	DREN	
AGE		VACCINE	DOSE
At birth	BCG for newborns born to parents originally	from endemic countries	Single Dose
	Hepatitis B for newborns  Diphtheria Pertussis Tetanus (DaPT) Hens	atitis B, Haemophilus Influenza Type B (Hib) + Inactivated	Birth Dose
24 74 74 74 74 74 74 74 74 74 74 74 74 74	Polio ( as Hexavalent)	ands b, Flaemophilius initidenza Type b (Filb) + inactivated	1 <sup>st</sup> Dose
2 months	Pneumococcal Conjugate (PCV)	1 <sup>st</sup> Dose	
	Rota vaccine (oral)	1 <sup>st</sup> Dose	
	Diphtheria, Pertussis, Tetanus (DaPT), Hepa	2 <sup>nd</sup> Dose	
	Polio ( as Hexavalent)		
4 months	Oral Polio Vaccine (OPV) Pneumococcal Conjugate (PCV)	2 <sup>nd</sup> Dose 2 <sup>nd</sup> Dose	
	Rota vaccine (oral)	2 Dose 2 <sup>nd</sup> Dose	
	DPT, Hepatitis B, Hib (as Pentavalent)	3 <sup>rd</sup> Dose	
6 months	Oral Polio Vaccine (OPV)	3 <sup>rd</sup> Dose	
12 months	Measles, Mumps, Rubella (MMR)	1 <sup>st</sup> Dose	
12 months		1 <sup>st</sup> Dose	
15 months	Pneumococcal Conjugate (PCV)		Booster
10 months	Hepatitis A	1 <sup>st</sup> Dose	
0.00	Measles, Mumps, Rubella (MMR)	2 <sup>nd</sup> Dose	
18 months	Tetravalent (DPT, Hib) or Pentavalent accord	1 <sup>st</sup> Booster	
	Oral Polio Vaccine (OPV)		1 <sup>st</sup> Booster
2 years	Meningococcal Conjugate (ACYW)		Single Dose
	Hepatitis A		2 <sup>nd</sup> Dose
3 years	Varicella Diphtheria, Tetanus, Pertussis, Inactivated P	Polio (DTaP IDV)	2 <sup>nd</sup> Dose 2 <sup>nd</sup> Booster
	Oral Polio Vaccine (OPV)	olio (DTAP-IPV)	2 <sup>nd</sup> Booster 2 <sup>nd</sup> Booster
4-5 years	V. A.		Catch up dose (if no
	Measles, Mumps, Rubella (MMR) if no docur	ment of 2 valid doses of MMR vaccination previously.	completed)
	ADOLE:	SCENTS	completed)
13 years	Tetanus, Diphtheria, acellular Pertussis (Tda		Booster
			Doosiei
		MEN AT REPRODUCTIVE AGE GROUP	
	At first contact		Td1
P-4	At least 4 weeks after Td1 At least 6 months after Td2	Td2	
etanus diphtheria (Td)	1 year after Td3	Td3	
		Td 1 <sup>st</sup> booster Td 2 <sup>nd</sup> booster	
	1 year after Td 15t booster	D. HIGH BIOK ODGUDO	1d 2 booster
	ADULT, ELDERLY AN	D HIGH RISK GROUPS	
Pneumococcal Conjugate	Single dose for adolescent, adult and elderly	from high risk groups. Single dose for adults ≥ 50 years a	nd elderly.
(PCV)	Single dose for 3 65 years and for high rights	groups ≥ 2-64 years. Revaccination dose after 5 years is re	
Pneumococcal		groups ≥ 2-64 years. Revaccination dose after 5 years is re ase/other hemaglobinopathies, congenital or acquired aspl	
Polysaccharide (PPSV23)	acquired immuno-deficiencies, chronic renal		
.,,,	immunosuppression, solid organ transplant).		
Tdap	Single dose might be given to those at risk of		
	Annually for each season from age of ≥ 6 mc	onths. It is recommended to certain risk categories (children	n≥ ≤ 5 years,
	adults/elderly ≥ 50 years and certain chronic	medical conditions such as: chronic pulmonary diseases.	chronic cardiovascul
Seasonal Influenza	adults/elderly ≥ 50 years and certain chronic diseases, chronic renal diseases, chronic he	medical conditions such as: chronic pulmonary diseases, patic diseases, chronic hematological conditions, chronic n	chronic cardiovascul netabolic disorders
Seasonal Influenza	adults/elderly ≥ 50 years and certain chronic diseases, chronic renal diseases, chronic he including diabetes mellitus, chronic neurologi	medical conditions such as: chronic pulmonary diseases, patic diseases, chronic hematological conditions, chronic nic and neurodevelopment conditions, Immune-suppressed	chronic cardiovascul netabolic disorders individuals by
Seasonal Influenza	adults/elderly ≥ 50 years and certain chronic diseases, chronic renal diseases, chronic hel including diabetes mellitus, chronic neurologi medications or by disease condition, pregnar	medical conditions such as: chronic pulmonary diseases, patic diseases, chronic hematological conditions, chronic n	chronic cardiovascul netabolic disorders individuals by
	adults/elderly ≥ 50 years and certain chronic diseases, chronic renal diseases, chronic he including diabetes mellitus, chronic neurologi medications or by disease condition, pregnar treating physician).	medical conditions such as: chronic pulmonary diseases, patic diseases, chronic hematological conditions, chronic nic and neurodevelopment conditions, Immune-suppressed	chronic cardiovascul netabolic disorders individuals by to be determined by
	adults/elderly ≥ 50 years and certain chronic diseases, chronic renal diseases, chronic her including diabetes mellitus, chronic neurologi medications or by disease condition, pregnar treating physician).  For certain risk groups without documented in as 2 doses 4 weeks apart for ≥ 13 years of as	medical conditions such as: chronic pulmonary diseases, patic diseases, chronic hematological conditions, chronic nic and neurodevelopment conditions, Immune-suppressed int women, health care workers and other categories at risk infection or vaccination. Two doses, 3 months apart from 1 ge.	chronic cardiovascul netabolic disorders individuals by to be determined by -12 years of age an
Varicella (Chickenpox)	adults/elderly ≥ 50 years and certain chronic diseases, chronic renal diseases, chronic hel including diabetes mellitus, chronic neurologi medications or by disease condition, pregnar treating physician).  For certain risk groups without documented in as 2 doses 4 weeks apart for ≥ 13 years of a Single dose to certain risk groups and travele	medical conditions such as: chronic pulmonary diseases, patic diseases, chronic hematological conditions, chronic n ic and neurodevelopment conditions, Immune-suppressed in women, health care workers and other categories at risk infection or vaccination. Two doses, 3 months apart from 1 ge.  ers to Holly places, meningitis belt countries and countries	chronic cardiovascul netabolic disorders individuals by to be determined by -12 years of age and reporting outbreak.
Seasonal Influenza  Varicella (Chickenpox)  Meningococcal conjugate	adults/elderly ≥ 50 years and certain chronic diseases, chronic renal diseases, chronic hei including diabetes mellitus, chronic neurologi medications or by disease condition, pregnar treating physician).  For certain risk groups without documented in as 2 doses 4 weeks apart for ≥ 13 years of as Single dose to certain risk groups and travele Booster doses every 5 years is given for cert	medical conditions such as: chronic pulmonary diseases, patic diseases, chronic hematological conditions, chronic n ic and neurodevelopment conditions, Immune-suppressed in women, health care workers and other categories at risk infection or vaccination. Two doses, 3 months apart from 1 ge.  ge.  ges to Holly places, meningitis belt countries and countries tain categories remain at risk of infection such as: functional	chronic cardiovascul netabolic disorders individuals by to be determined by -12 years of age and reporting outbreak.
Varicella (Chickenpox) Meningococcal conjugate ACWY	adults/elderly ≥ 50 years and certain chronic diseases, chronic renal diseases, chronic hei including diabetes mellitus, chronic neurologi medications or by disease condition, pregnar treating physician).  For certain risk groups without documented in as 2 doses 4 weeks apart for ≥ 13 years of a Single dose to certain risk groups and traveled Booster doses every 5 years is given for cert asplenia (including sickle cell disease), persist	medical conditions such as: chronic pulmonary diseases, patic diseases, chronic hematological conditions, chronic n ic and neurodevelopment conditions, Immune-suppressed in women, health care workers and other categories at risk infection or vaccination. Two doses, 3 months apart from 1 ge.  ers to Holly places, meningitis belt countries and countries lain categories remain at risk of infection such as: functions stent complement component deficiency and people with health of the complement component deficiency and people with health of the complement component deficiency and people with health of the complement component deficiency and people with health of the complement component deficiency and people with health of the complement component deficiency and people with health of the complement component deficiency and people with health of the categories remains at the complement component deficiency and people with health of the categories are complement component deficiency and people with health of the categories are categories at the categories at the categories and the categories at the	chronic cardiovascul netabolic disorders individuals by to be determined by -12 years of age and reporting outbreak. If or anatomical ally infection.
Varicella (Chickenpox) Meningococcal conjugate ACWY Haemophilus Influenza	adults/elderly ≥ 50 years and certain chronic diseases, chronic renal diseases, chronic her including diabetes mellitus, chronic neurologi medications or by disease condition, pregnar treating physician).  For certain risk groups without documented in as 2 doses 4 weeks apart for ≥ 13 years of a Single dose to certain risk groups and travelet Booster doses every 5 years is given for cert asplenia (including sickle cell disease), persis Single dose for >5 years of age having any o	medical conditions such as: chronic pulmonary diseases, patic diseases, chronic hematological conditions, chronic n ic and neurodevelopment conditions, Immune-suppressed in women, health care workers and other categories at risk infection or vaccination. Two doses, 3 months apart from 1 ge.  ers to Holly places, meningitis belt countries and countries ain categories remain at risk of infection such as: functional stent complement component deficiency and people with Fof the following conditions: sickle cell disease, anatomical a	chronic cardiovascul netabolic disorders individuals by to be determined by -12 years of age and reporting outbreak. al or anatomical HV infection.
Varicella (Chickenpox) Meningococcal conjugate ACWY	adults/elderly ≥ 50 years and certain chronic diseases, chronic renal diseases, chronic hei including diabetes mellitus, chronic neurologi medications or by disease condition, pregnar treating physician).  For certain risk groups without documented is as 2 doses 4 weeks apart for ≥ 13 years of as Single dose to certain risk groups and travelet Booster doses every 5 years is given for cert asplenia (including sickle cell disease), persis Single dose for >5 years of age having any of asplenia, post bone marrow transplant and certain risk groups.	medical conditions such as: chronic pulmonary diseases, patic diseases, chronic hematological conditions, chronic n ic and neurodevelopment conditions, Immune-suppressed in women, health care workers and other categories at risk infection or vaccination. Two doses, 3 months apart from 1 ge.  sers to Holly places, meningitis belt countries and countries are to the total places, infection such as: functions stent complement component deficiency and people with hof the following conditions: sickle cell disease, anatomical a certain cancer after completion of treatment.	chronic cardiovascul netabolic disorders individuals by to be determined by -12 years of age and reporting outbreak. al or anatomical HV infection.
Varicella (Chickenpox) Weningococcal conjugate ACWY Haemophilus Influenza Type B (Hib)	adults/elderly ≥ 50 years and certain chronic diseases, chronic renal diseases, chronic hei including diabetes mellitus, chronic neurologi medications or by disease condition, pregnar treating physician).  For certain risk groups without documented is as 2 doses 4 weeks apart for ≥ 13 years of as Single dose to certain risk groups and travelet Booster doses every 5 years is given for cert asplenia (including sickle cell disease), persis Single dose for >5 years of age having any of asplenia, post bone marrow transplant and cell.	medical conditions such as: chronic pulmonary diseases, patic diseases, chronic hematological conditions, chronic n ic and neurodevelopment conditions, Immune-suppressed nt women, health care workers and other categories at risk infection or vaccination. Two doses, 3 months apart from 1 ge.  ers to Holly places, meningitis belt countries and countries ain categories remain at risk of infection such as: functions stent complement component deficiency and people with hof the following conditions: sickle cell disease, anatomical a ertain cancer after completion of treatment.	chronic cardiovascul netabolic disorders individuals by to be determined by -12 years of age and reporting outbreak. al or anatomical HV infection.
Varicella (Chickenpox) Meningococcal conjugate ACWY Haemophilus Influenza Type B (Hib) Meningococcal conjugate (A	adults/elderly ≥ 50 years and certain chronic diseases, chronic renal diseases, chronic hei including diabetes mellitus, chronic neurologi medications or by disease condition, pregnar treating physician).  For certain risk groups without documented is as 2 doses 4 weeks apart for ≥ 13 years of as Single dose to certain risk groups and travelet Booster doses every 5 years is given for cert asplenia (including sickle cell disease), persis Single dose for >5 years of age having any of asplenia, post bone marrow transplant and cell.	medical conditions such as: chronic pulmonary diseases, patic diseases, chronic hematological conditions, chronic nic and neurodevelopment conditions, Immune-suppressed in women, health care workers and other categories at risk infection or vaccination. Two doses, 3 months apart from 1 ge, ers to Holly places, meningitis belt countries and countries tain categories remain at risk of infection such as: functional stent complement component deficiency and people with both the following conditions: sickle cell disease, anatomical a certain cancer after completion of treatment.  Jils  Single dose	chronic cardiovascul netabolic disorders individuals by to be determined by -12 years of age and reporting outbreak. If or anatomical ally infection.
Varicella (Chickenpox) Meningococcal conjugate ACWY Haemophilus Influenza Type B (Hib) Meningococcal conjugate (A	adults/elderly ≥ 50 years and certain chronic diseases, chronic renal diseases, chronic her including diabetes mellitus, chronic neurologi medications or by disease condition, pregnar treating physician).  For certain risk groups without documented in as 2 doses 4 weeks apart for ≥ 13 years of at Single dose to certain risk groups and travelet Booster doses every 5 years is given for cert asplenia (including sickle cell disease), persist Single dose for >5 years of age having any of asplenia, post bone marrow transplant and cell.  HA.	medical conditions such as: chronic pulmonary diseases, patic diseases, chronic hematological conditions, chronic n ic and neurodevelopment conditions, Immune-suppressed in women, health care workers and other categories at risk infection or vaccination. Two doses, 3 months apart from 1 ge, ers to Holly places, meningitis belt countries and countries tain categories remain at risk of infection such as: functions stent complement component deficiency and people with both the following conditions: sickle cell disease, anatomical a certain cancer after completion of treatment.  Jils  Single dose  Annually for each season	chronic cardiovascul netabolic disorders individuals by to be determined by -12 years of age and reporting outbreak. If or anatomical ally infection.
Varicella (Chickenpox) Meningococcal conjugate ACWY Haemophilus Influenza Type B (Hib) Meningococcal conjugate (A	adults/elderly ≥ 50 years and certain chronic diseases, chronic renal diseases, chronic hele including diabetes mellitus, chronic neurologi medications or by disease condition, pregnar treating physician).  For certain risk groups without documented in as 2 doses 4 weeks apart for ≥ 13 years of a Single dose to certain risk groups and travele Booster doses every 5 years is given for cert asplenia (including sickle cell disease), persis Single dose for >5 years of age having any of asplenia, post bone marrow transplant and characteristics.  HA.	medical conditions such as: chronic pulmonary diseases, patic diseases, chronic hematological conditions, chronic nic and neurodevelopment conditions, Immune-suppressed in women, health care workers and other categories at risk infection or vaccination. Two doses, 3 months apart from 1 ge.  Ders to Holly places, meningitis belt countries and countries that categories remain at risk of infection such as: functions stent complement component deficiency and people with but the following conditions: sickle cell disease, anatomical a certain cancer after completion of treatment.  JIIS  Single dose  Annually for each season  (ACCINES)	chronic cardiovascul netabolic disorders individuals by to be determined by -12 years of age and reporting outbreak. al or anatomical HIV infection.
Varicella (Chickenpox) Meningococcal conjugate ACWY Haemophilus Influenza Type B (Hib) Meningococcal conjugate (A	adults/elderly ≥ 50 years and certain chronic diseases, chronic renal diseases, chronic neurologi medications or by disease condition, pregnar treating physician).  For certain risk groups without documented in as 2 doses 4 weeks apart for ≥ 13 years of as Single dose to certain risk groups and travele Booster doses every 5 years is given for cert asplenia (including sickle cell disease), persis Single dose for >5 years of age having any of asplenia, post bone marrow transplant and companies.  ACWY)  OTHER V	medical conditions such as: chronic pulmonary diseases, patic diseases, chronic hematological conditions, chronic n ic and neurodevelopment conditions, Immune-suppressed in women, health care workers and other categories at risk infection or vaccination. Two doses, 3 months apart from 1 ge.  ers to Holly places, meningitis belt countries and countries ain categories remain at risk of infection such as: functional stent complement component deficiency and people with Fig. 1 for the following conditions: sickle cell disease, anatomical a certain cancer after completion of treatment.  Jils  Single dose  Annually for each season  (ACCINES  Single dose	chronic cardiovascul netabolic disorders individuals by to be determined by -12 years of age and reporting outbreak, all or anatomical IIV infection, ind/or surgical
Varicella (Chickenpox) Meningococcal conjugate ACWY Haemophilus Influenza Type B (Hib) Meningococcal conjugate (ACC) Geasonal Influenza	adults/elderly ≥ 50 years and certain chronic diseases, chronic renal diseases, chronic hel including diabetes mellitus, chronic neurologi medications or by disease condition, pregnar treating physician).  For certain risk groups without documented in as 2 doses 4 weeks apart for ≥ 13 years of as Single dose to certain risk groups and travele Booster doses every 5 years is given for cert asplenia (including sickle cell disease), persis Single dose for >5 years of age having any of asplenia, post bone marrow transplant and company to the control of the co	medical conditions such as: chronic pulmonary diseases, patic diseases, chronic hematological conditions, chronic n ic and neurodevelopment conditions, Immune-suppressed in women, health care workers and other categories at risk infection or vaccination. Two doses, 3 months apart from 1 ge.  ers to Holly places, meningitis belt countries and countries ain categories remain at risk of infection such as: functional stent complement component deficiency and people with both the following conditions: sickle cell disease, anatomical attention cancer after completion of treatment.  Jils  Single dose  Annually for each season  ACCINES  Single dose  Single dose (typhoid polysaccharide is repeated after 3)	chronic cardiovascul netabolic disorders individuals by to be determined by -12 years of age an reporting outbreak. al or anatomical IIV infection. ind/or surgical
Varicella (Chickenpox) Meningococcal conjugate ACWY Haemophilus Influenza Type B (Hib) Meningococcal conjugate (ACM) Seasonal Influenza Travelers (according to trav	adults/elderly ≥ 50 years and certain chronic diseases, chronic renal diseases, chronic hei including diabetes mellitus, chronic neurologi medications or by disease condition, pregnar treating physician).  For certain risk groups without documented is as 2 doses 4 weeks apart for ≥ 13 years of as Single dose to certain risk groups and travele Booster doses every 5 years is given for cert asplenia (including sickle cell disease), persis Single dose for >5 years of age having any of asplenia, post bone marrow transplant and cell HA.  ACWY)  OTHER V  Yellow Fever  Typhoid  Hepatitis A	medical conditions such as: chronic pulmonary diseases, patic diseases, chronic hematological conditions, chronic n ic and neurodevelopment conditions, Immune-suppressed in women, health care workers and other categories at risk infection or vaccination. Two doses, 3 months apart from 1 ge.  ers to Holly places, meningitis belt countries and countries ain categories remain at risk of infection such as: functional stent complement component deficiency and people with health of the following conditions: sickle cell disease, anatomical alertain cancer after completion of treatment.  Jils  Single dose  Annually for each season  ACCINES  Single dose  Single dose (typhoid polysaccharide is repeated after 3-2 doses (if not vaccinated previously)	chronic cardiovascul netabolic disorders individuals by to be determined by -12 years of age an reporting outbreak. al or anatomical IIV infection. ind/or surgical
Varicella (Chickenpox) Meningococcal conjugate ACWY Haemophilus Influenza Type B (Hib) Meningococcal conjugate (ACM) Seasonal Influenza Travelers (according to trav	adults/elderly ≥ 50 years and certain chronic diseases, chronic renal diseases, chronic hei including diabetes mellitus, chronic neurologi medications or by disease condition, pregnar treating physician).  For certain risk groups without documented is as 2 doses 4 weeks apart for ≥ 13 years of as Single dose to certain risk groups and travele Booster doses every 5 years is given for cert asplenia (including sickle cell disease), persis Single dose for >5 years of age having any of asplenia, post bone marrow transplant and cell the company of the cell the	medical conditions such as: chronic pulmonary diseases, patic diseases, chronic hematological conditions, chronic n ic and neurodevelopment conditions, Immune-suppressed in women, health care workers and other categories at risk infection or vaccination. Two doses, 3 months apart from 1 ge, ers to Holly places, meningitis belt countries and countries ain categories remain at risk of infection such as: functions stent complement component deficiency and people with Hof the following conditions: sickle cell disease, anatomical a certain cancer after completion of treatment.  JIIS  Single dose  Annually for each season  ACCINES  Single dose  Single dose (typhoid polysaccharide is repeated after 3 2 doses (if not vaccinated previously)  Single dose for traveler to certain countries	chronic cardiovascul netabolic disorders individuals by to be determined by -12 years of age an reporting outbreak. al or anatomical HV infection. ind/or surgical  years if indicated)
Varicella (Chickenpox)  Meningococcal conjugate ACWY  Haemophilus Influenza Type B (Hib)  Meningococcal conjugate (ACM)  Seasonal Influenza  Travelers (according to travelestination)	adults/elderly ≥ 50 years and certain chronic diseases, chronic renal diseases, chronic hei including diabetes mellitus, chronic neurologi medications or by disease condition, pregnar treating physician).  For certain risk groups without documented in as 2 doses 4 weeks apart for ≥ 13 years of at Single dose to certain risk groups and travele Booster doses every 5 years is given for cert asplenia (including sickle cell disease), persist Single dose for >5 years of age having any of asplenia, post bone marrow transplant and companies.  ACWY)  OTHER V  Yellow Fever  Typhoid  Hepatitis A  Meningococcal conjugate ACWY  OPV/IPV	medical conditions such as: chronic pulmonary diseases, patic diseases, chronic hematological conditions, chronic n ic and neurodevelopment conditions, Immune-suppressed in women, health care workers and other categories at risk infection or vaccination. Two doses, 3 months apart from 1 ge.  ers to Holly places, meningitis belt countries and countries ain categories remain at risk of infection such as: functional stent complement component deficiency and people with health of the following conditions: sickle cell disease, anatomical alertain cancer after completion of treatment.  Jils  Single dose  Annually for each season  ACCINES  Single dose  Single dose (typhoid polysaccharide is repeated after 3-2 doses (if not vaccinated previously)	chronic cardiovascul netabolic disorders individuals by to be determined by -12 years of age an reporting outbreak. al or anatomical HV infection. ind/or surgical  years if indicated)
Varicella (Chickenpox) Meningococcal conjugate ACWY Haemophilus Influenza Type B (Hib) Meningococcal conjugate (ACC) Geasonal Influenza Travelers (according to travelestination) Post exposure prophylaxis	adults/elderly ≥ 50 years and certain chronic diseases, chronic renal diseases, chronic hei including diabetes mellitus, chronic neurologi medications or by disease condition, pregnar treating physician).  For certain risk groups without documented in as 2 doses 4 weeks apart for ≥ 13 years of as Single dose to certain risk groups and travele Booster doses every 5 years is given for cert asplenia (including sickle cell disease), persist Single dose for >5 years of age having any of asplenia, post bone marrow transplant and compared to the control of the	medical conditions such as: chronic pulmonary diseases, patic diseases, chronic hematological conditions, chronic n ic and neurodevelopment conditions, Immune-suppressed in women, health care workers and other categories at risk infection or vaccination. Two doses, 3 months apart from 1 ge.  ers to Holly places, meningitis belt countries and countries tain categories remain at risk of infection such as: functional stent complement component deficiency and people with hof the following conditions: sickle cell disease, anatomical attraction cancer after completion of treatment.  Jils  Single dose  Annually for each season  ACCINES  Single dose  Single dose (typhoid polysaccharide is repeated after 3 2 doses (if not vaccinated previously)  Single dose for traveler to certain countries  Booster dose for traveler to Polio endemic/ Polio reporting	chronic cardiovascul netabolic disorders individuals by to be determined by -12 years of age an reporting outbreak. al or anatomical HV infection. ind/or surgical  years if indicated)
Varicella (Chickenpox) Meningococcal conjugate ACWY Haemophilus Influenza Type B (Hib) Meningococcal conjugate (ACC) Geasonal Influenza Travelers (according to travelestination) Post exposure prophylaxis	adults/elderly ≥ 50 years and certain chronic diseases, chronic renal diseases, chronic renal diseases, chronic hele including diabetes mellitus, chronic neurologic medications or by disease condition, pregnar treating physician).  For certain risk groups without documented is a 2 doses 4 weeks apart for ≥ 13 years of a Single dose to certain risk groups and travelet Booster doses every 5 years is given for cert asplenia (including sickle cell disease), persist Single dose for >5 years of age having any of asplenia, post bone marrow transplant and companies, post bone marrow transplant and companies.  **ACWY**  OTHER V**  Yellow Fever*  Typhoid**  Hepatitis A**  Meningococcal conjugate ACWY*  OPV/IPV*  (depend dory)**  Rabies*	medical conditions such as: chronic pulmonary diseases, patic diseases, chronic hematological conditions, chronic nic and neurodevelopment conditions, Immune-suppressed in women, health care workers and other categories at risk infection or vaccination. Two doses, 3 months apart from 1 ge.  Bers to Holly places, meningitis belt countries and countries are categories remain at risk of infection such as: functions stent complement component deficiency and people with both the following conditions: sickle cell disease, anatomical a certain cancer after completion of treatment.  JIIS  Single dose  Annually for each season  ACCINES  Single dose  Single dose  Single dose  Single dose (typhoid polysaccharide is repeated after 3 2 doses (if not vaccinated previously)  Single dose for traveler to certain countries  Booster dose for traveler to Polio endemic/ Polio reportir 4 doses plus RIG (single)	chronic cardiovascul netabolic disorders individuals by to be determined by -12 years of age an reporting outbreak. al or anatomical HV infection. ind/or surgical  years if indicated)
Varicella (Chickenpox)  Meningococcal conjugate ACWY  Haemophilus Influenza Type B (Hib)  Meningococcal conjugate (ACC) Seasonal Influenza  Travelers (according to travelestination)  Post exposure prophylaxis on exposure and risk categoria.	adults/elderly ≥ 50 years and certain chronic diseases, chronic renal diseases, chronic neurologi medications or by disease condition, pregnar treating physician).  For certain risk groups without documented in as 2 doses 4 weeks apart for ≥ 13 years of as Single dose to certain risk groups and travele Booster doses every 5 years is given for cert asplenia (including sickle cell disease), persis Single dose for >5 years of age having any o asplenia, post bone marrow transplant and compared to the provided Hepatitis A Meningococcal conjugate ACWY  (depend OPV/IPV  (depend OPY)  Rabies  Hepatitis B	medical conditions such as: chronic pulmonary diseases, patic diseases, chronic hematological conditions, chronic n ic and neurodevelopment conditions, Immune-suppressed in women, health care workers and other categories at risk infection or vaccination. Two doses, 3 months apart from 1 ge.  ers to Holly places, meningitis belt countries and countries ain categories remain at risk of infection such as: functional stent complement component deficiency and people with high the following conditions: sickle cell disease, anatomical alertain cancer after completion of treatment.  Jils  Single dose  Annually for each season  ACCINES  Single dose  Single dose (typhoid polysaccharide is repeated after 3 2 doses (if not vaccinated previously)  Single dose for traveler to certain countries  Booster dose for traveler to Polio endemic/ Polio reportir 4 doses plus RIG (single)  3 doses	chronic cardiovascul netabolic disorders individuals by to be determined by -12 years of age an reporting outbreak. al or anatomical HV infection. ind/or surgical  years if indicated)
Varicella (Chickenpox) Meningococcal conjugate ACWY Haemophilus Influenza Type B (Hib) Meningococcal conjugate (ACC) Seasonal Influenza Travelers (according to travelestination) Post exposure prophylaxis on exposure and risk catego	adults/elderly ≥ 50 years and certain chronic diseases, chronic renal diseases, chronic renal diseases, chronic hele including diabetes mellitus, chronic neurologi medications or by disease condition, pregnar treating physician).  For certain risk groups without documented in as 2 doses 4 weeks apart for ≥ 13 years of as Single dose to certain risk groups and travele Booster doses every 5 years is given for cert asplenia (including sickle cell disease), persis Single dose for >5 years of age having any of asplenia, post bone marrow transplant and contain the post of the post	medical conditions such as: chronic pulmonary diseases, patic diseases, chronic hematological conditions, chronic nic and neurodevelopment conditions, Immune-suppressed in women, health care workers and other categories at risk infection or vaccination. Two doses, 3 months apart from 1 ge.  Bers to Holly places, meningitis belt countries and countries are categories remain at risk of infection such as: functions stent complement component deficiency and people with both the following conditions: sickle cell disease, anatomical a certain cancer after completion of treatment.  JIIS  Single dose  Annually for each season  ACCINES  Single dose  Single dose  Single dose  Single dose (typhoid polysaccharide is repeated after 3 2 doses (if not vaccinated previously)  Single dose for traveler to certain countries  Booster dose for traveler to Polio endemic/ Polio reportir 4 doses plus RIG (single)	chronic cardiovascul netabolic disorders individuals by to be determined by -12 years of age and reporting outbreak. all or anatomical HV infection. Ind/or surgical  years if indicated)
Varicella (Chickenpox) Meningococcal conjugate ACWY Haemophilus Influenza Type B (Hib) Meningococcal conjugate (ACC) Geasonal Influenza Travelers (according to travelestination) Post exposure prophylaxis on exposure and risk categorial	adults/elderly ≥ 50 years and certain chronic diseases, chronic renal diseases, chronic renal diseases, chronic hele including diabetes mellitus, chronic neurologi medications or by disease condition, pregnar treating physician).  For certain risk groups without documented in as 2 doses 4 weeks apart for ≥ 13 years of as Single dose to certain risk groups and travele Booster doses every 5 years is given for cert asplenia (including sickle cell disease), persis Single dose for >5 years of age having any of asplenia, post bone marrow transplant and contain the post of the post	medical conditions such as: chronic pulmonary diseases, patic diseases, chronic hematological conditions, chronic n ic and neurodevelopment conditions, Immune-suppressed in women, health care workers and other categories at risk infection or vaccination. Two doses, 3 months apart from 1 ge.  ers to Holly places, meningitis belt countries and countries ain categories remain at risk of infection such as: functional stent complement component deficiency and people with high the following conditions: sickle cell disease, anatomical alertain cancer after completion of treatment.  Jils  Single dose  Annually for each season  ACCINES  Single dose  Single dose (typhoid polysaccharide is repeated after 3 2 doses (if not vaccinated previously)  Single dose for traveler to certain countries  Booster dose for traveler to Polio endemic/ Polio reportir 4 doses plus RIG (single)  3 doses	chronic cardiovascul netabolic disorders individuals by to be determined by -12 years of age an reporting outbreak. al or anatomical HV infection. ind/or surgical  years if indicated)

Copyright  $\circ$  by Ministry of Health, Kingdom of Bahrain, 2018, All Rights Reserved

Prepared by: EPI Group

Design by: Ali AlMawali



# **VACCINATION CONSENT FORM**

Dear parent of student:
CPR: Class: G 8/
According to the immunization schedule in kingdom of Bahrain, Tdap (A booster dose)
is scheduled to be given to students at the 2 <sup>nd</sup> intermediate class. Accordingly, a team
of school health nurses from Ministry of Health will conduct a vaccination session that
include administration of the vaccine to 13 years old child.
- Tetanus, diphtheria acellular pertussis vaccine (Tdap booster dose).
Your consent of agreement is kindly requested.
Thanking you for your cooperation.
Do not consent (give reason)
My child received the vaccine at the private clinic on/
Note: Attach prove document of vaccination.
Date:/ Name of Parent:
Signature of parent:

